FibroBiologics Inc. is facing potential delisting from the Nasdaq Capital Market after its common stock price remained below the required $1.00 minimum bid for 30 consecutive trading days, violating Nasdaq Listing Rule 5550(a)(2). The company received a notice from Nasdaq and was given 180 days, until December 29, 2025, to regain compliance. After failing to do so, FibroBiologics received a second notice indicating that Nasdaq staff intends to delist its securities, although a hearing request by the company will temporarily halt any delisting actions. To address the issue, the company has proposed a reverse stock split, subject to shareholder approval, but there is no guarantee these efforts will succeed or that an extension will be granted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-001077), on January 02, 2026, and is solely responsible for the information contained therein.